ducovest

SBIO:NYE-ALPS Medical Breakthroughs ETF (USD)

ETF | Health |

Last Closing

USD 38.2607

Change

0.00 (0.00)%

Market Cap

USD 0.12B

Volume

6.83K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Company Website : http://www.alpsfunds.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

N/A

 USD 40.26B
FHLC Fidelity® MSCI Health Care In..

N/A

 USD 2.86B
FXH First Trust Health Care AlphaD..

N/A

 USD 1.18B
XHE SPDR® S&P Health Care Equipme..

N/A

 USD 0.21B
IDNA iShares Genomics Immunology an..

N/A

 USD 0.14B
XHS SPDR® S&P Health Care Service..

N/A

 USD 0.08B
HTEC Robo Global® Healthcare Techn..

N/A

 USD 0.05B
BBP Virtus LifeSci Biotech Product..

N/A

 USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

N/A

 USD 0.01B
IHE iShares U.S. Pharmaceuticals E..

N/A

 N/A

ETFs Containing SBIO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.15% 95% A 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.15% 95% A 74% C
Trailing 12 Months  
Capital Gain 46.26% 95% A 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.26% 95% A 86% B+
Trailing 5 Years  
Capital Gain 5.99% 57% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.99% 57% F 56% F
Average Annual (5 Year Horizon)  
Capital Gain -0.21% 19% F 32% F
Dividend Return -0.17% 19% F 22% F
Total Return 0.04% 16% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 27.43% 29% F 38% F
Risk Adjusted Return -0.60% 19% F 22% F
Market Capitalization 0.12B 50% F 30% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.